Publication details
Pegaptanib (Macugen) v léčbě vlhké formy věkem podmíněné makulární degenerace, 1,5 leté zkušenosti
| Title in English | Pegaptanib (Macugen) in treatment of wet form of age related macular degeneration, 1.5 year experience |
|---|---|
| Authors | |
| Year of publication | 2009 |
| Type | Article in Proceedings |
| Conference | Sborník abstrakt XVII. výročního sjezdu České oftalmologické společnosti |
| MU Faculty or unit | |
| Citation | |
| Field | ORL, ophthalmology, stomatology |
| Keywords | age related macular degeneration; choroidal neovascular membrane; vascular endothelial growth factor; pegaptanib |
| Description | Authors in their work assess the results achieved by the use of pegaptanib (Macugen, a) for treatment of wet age-related macular degeneration (AMD). Pegaptanib (Macugen, Pfizer) is the first antagonist of the vascular growth factor (VEGF), approved for intraocular injection in the wet form of age-related macular degeneration (AMD). Pegaptanib is used in our department to treat patients with occult or minimally classic subretinal neovascular membrane (CNV) in the subfoveal location. Patients included in the sample are treated with repeated intraocular pegaptanib applications at an interval of 6 weeks (total of 9 injections over 12 months). Treatment of patients at the time of writing the abstract is still ongoing. Results will |